论文部分内容阅读
2012年,注定是医药行业不平凡的一年。2011年底,国务院总理温家宝主持召开国务院常务会议,讨论通过了《国家药品安全规划(2011-2015年)》,明确了7项重点工作任务。此举无疑预示着2012年医改新政大幕正式拉开我们仍清晰记得2009年4月开始实施的投资8500亿元人民币的医疗改革,当时提出的目标是到2020年实现全民医保。消息一经传出,不仅全国普通人民为之一振,也激发了许多中外制药厂商和医疗器械制造商的壮志雄心。他们在国家加大财政资金投入、扩大医保覆盖
2012 is destined to be an extraordinary year for the pharmaceutical industry. At the end of 2011, Premier Wen Jiabao chaired a State Council executive meeting to discuss and pass the “National Drug Safety Plan (2011-2015)”, clearly defined seven key tasks. This will undoubtedly signal the curtain-breaking reform of the medical reform in 2012. We still clearly remember the 850 billion yuan investment in healthcare launched in April 2009, when the goal was to achieve universal health coverage by 2020. As soon as the news came out, not only did the ordinary people in the country revitalize it, but also the ambitions of many Chinese and foreign pharmaceutical manufacturers and manufacturers of medical devices. They have increased their financial investment in the country and expanded coverage of health insurance